Discovery of a Highly Potent and Selective BRD9 PROTAC Degrader Based on E3 Binder Investigation for the Treatment of Hematological TumorsHaiting Duan, Jinxin Che, Ao Pang et al.|Journal of Medicinal Chemistry|2024Cited by 19
Structure-based identification of new orally bioavailable BRD9-PROTACs for treating acute myelocytic leukemiaJingyu Zhang, Jinxin Che, Haiting Duan et al.|European Journal of Medicinal Chemistry|2023Cited by 14